Botulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October :00-17:00
|
|
- Cornelia Freeman
- 6 years ago
- Views:
Transcription
1 Botulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October :00-17:00 Start End Topic Speakers 14:00 14:15 Introduction Mohammad Khan 14:15 14:40 Botulinum toxin-a to treat neurogenic detrusor Jalesh Panicker overactivity 14:40 14:50 Questions All 14:50 15:15 Botulinum toxin-a to treat refractory OAB and other Arun Sahai forms of bladder dysfunction 15:15 15:30 Questions All 15:30 16:00 Break None 16:00 16:20 Mechanism of action of botulinum toxin-a in the Prokar Dasgupta bladder 16:20 16:30 Questions All 16:30 16:50 Patient assessment, technique of administration, Mohammad Khan tips and tricks in the use of bladder BTX-A 16:50 17:00 Questions All Aims of course/workshop Botulinum toxin is an effective 2nd line treatment option for treating refractory overactive bladder syndrome and detrusor overactivity. This workshop will provide an overview of the published literature on the subject but will focus on level I evidence from randomized placebo controlled trials. Its use in bladder oversensitivity and painful bladder syndrome will also be discussed. Current knowledge on mechanism of action will be presented. The workshop will deliver practical points, technical aspects of drug delivery, tips and tricks which will be helpful to both new and established users. Educational Objectives Botulinum toxin is now recognised treatment for refractory OAB and is included in many incontinence guidelines such as EAU and NICE. It has recently obtained FDA approval for treating neurogenic bladder and its use amongst clinicians involved in overactive bladder management is increasing worldwide. This workshop will concentrate on synthesizing the vast volumes of published literature on the subject and presenting it to the participant in a succinct, meaningful way, specifically focusing on level I evidence. Furthermore patient assessment, technique of administration, tips, tricks and practical points will be discussed which will aid both clinicians starting up a service or with an established practice to ensure safe and effective treatment of their patients. The workshop will allow plenty of time for discussion with the faculty, all of whom have an extensive experience with the use of botulinum toxin and a good track record in the published literature in this area.
2 Botulinum toxin in NDO Jalesh Panicker Consultant Neurologist in Uro-Neurology The National Hospital for Neurology and Neurosurgery, Honorary Senior Lecturer, UCL Institute of Neurology Queen Square, London, UK ICS Beijing October 2012 Licensed indications (UK) Paediatric cerebral palsy Focal spasticity associated with stroke Hemifacial spasm Blepharospasm Cervical dystonia Hyperhidrosis Cosmesis Onabotulinum toxin Abobotulinum toxin Case 48, female Multiple sclerosis- 10 years; secondary progresssive Optic neuritis, paraparesis Uses one stick support for walking Urgency, frequency, incontinence Hesitancy, straining, double voiding Previously: PVR 70 ml, started oxybutinin 15 mg/day- urgency worsened MS- a demyelinating disorder 1
3 Bladder scan: 120 ml PVR Dipstick negative Antimuscarinics; DDAVP Bladder retraining; fluid regulation; exercises Antimuscarinics + CISC Botulinum toxin Indwelling catheter/ surgery Fowler, Panicker, et al., JNNP, 2009 Literature overview: 2000 to 2007 (Q4) Search PubMed: botulinum AND bladder NOT sphincter NOT prostate
4 Mean increase in MCC from baseline (ml) Increase in Total I-QoL Score from baseline (%) Reduction in number of UI episodes compared to baseline (%) Results: Urgency Incontinence U BoNT 200U BoNT Placebo Week 2 Week 6 Week 12 Week 18 Week 24 *p<0.05 for differences between BoNT group and placebo p<0.05 for difference within-group changes from baseline Schurch. J Urol, 2005 Results: Urodynamics MCC U BoNT 200 U BoNT Placebo Week 2 Week 6 Week 24 *p<0.05 for within-group changes from baseline p<0.05 for pairwise contrasts between BoNT groups versus placebo * Results: Quality of Life 300 U BoNT 200 U BoNT Placebo Week 2 Week 6 Week 12 Week 18 Week 24 *p<0.05 for pairwise contrasts between BoNT groups and placebo p for within-group differences from baseline Schurch. J Urol, 2005 Schurch. J Urol, 2005 Grosse et al.,
5 15 Improvement in urgency, frequency, incontinence, QOL in MS (n=43) 1st Injection Urogenital symptoms in MS (n=112) UDI6 Scores 80 Frequency Urgency * PRE 4/52 16/52 1st Injection * 1st Injection Incontinence * PRE 4/52 16/52 * PreBoNT/A 1 p<0.001 PostBoNT/A 1 PreBoNT/A 2 p<0.001 PostBoNT/A 2 PreBoNT/A 3 p<0.001 PostBoNT/A 3 PreBoNT/A 4 p<0.001 PostBoNT/A 4 PreBoNT/A 5 p=0.016 PostBoNT/A PRE 4/52 16/52 Kalsi et al., 2007 Khan et al. Poster BAUS, 2009 Incontinence Botulinum toxin for NDO (n=112) IIQ7 Scores PreBoNT/A 1 PostBoNT/A 1 PreBoNT/A 2 PostBoNT/A 2 PreBoNT/A 3 PostBoNT/A 3 PreBoNT/A 4 PostBoNT/A 4 PreBoNT/A 5 PostBoNT/A 5 p< p< p< p= p=0.136 Khan et al. Poster BAUS, 2009 Khan et al. Poster BAUS, Median inter injection interval (NDO/MS) Annual increase in workload 30 months Interval 1 Interval 2 Interval 3 Interval 4 Interval 5 Interval 6 p=0.6; 12.6 months (n=112, MS) Khan et al. Poster BAUS,
6 Time (Months) Open label study of 137 MS patients 60 Duration of action of Botox in 13 patients who had 4 injections Patient Number Khan S, et al. J Urol Apr;185(4): Cruz F, et al EAU Vienna March 2011 Cruz F, et al EAU Vienna March 2011 Herschorn et al NB. CISC taught with PVR 100 mls Khan S, et al. J Urol Apr;185(4):
7 Patient Perception - Before Patient Perception - After botulinum toxin A is the 21 st centenary penicillin for the bladder Cost effectiveness National Clinical Guideline Centre Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Consultation Draft February 2012 National Clinical Guideline Centre Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Consultation Draft February
8 Questions National Clinical Guideline Centre Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Consultation Draft February 2012 What about other neurological conditions? Which toxin is the best? What is the optimal dose? How many sites to inject? Should the trigone be avoided? Which dilution to use? Needle diameter? Conclusion Botulinum toxin is safe and effective in the management of NDO- level 1 evidence Attributes for the neurological patientminimally invasive, low side effects, duration of effect Potential need for catheterisation 7
9 OnabotulinumtoxinA to treat refractory OAB and other forms of bladder dysfunction Arun Sahai, Academic Clinical Lecturer in Urology ICS Workshop 2012, Beijing Objectives Formulations and terminology Literature Review OAB -Level 1 evidence -Key papers Repeated Injections Other types of bladder dysfunction Questions? Formulations Toxicity measured in mouse units (mu) amount fatal to 50% batch of swiss webster mice New Terminology Summary of FDA-Approved Botulinum Toxin Products Trade Name New Drug Name Old Drug Name Unlicensed currently for OAB / IDO Old Formulations Botulinum toxin-a: BOTOX, Allergan Ltd; DYSPORT, Ipsen Ltd 1 U BOTOX equivalent to 3-4 U of DYSPORT Botulinum Toxin-B: MYOBLOC /NEUROBLOC, Solstice Neurosciences Inc. Botox OnabotulinumtoxinA Botulinum toxin type A Botox Cosmetic OnabotulinumtoxinA Botulinum toxin type A Dysport AbobotulinumtoxinA Botulinum toxin type A Myobloc RimabotulinumtoxinA Botulinum toxin type B Urological applications of Botulinum Toxin IDO PBS / IC 2003 IDO Harper et al 2007 RCT IDO Sahai et al 2007 RCT NDO Ehren et al 2008 RCT IDO Brubaker et al 2009 RCT IDO Flynn et al 2010 Allergan Phase II multi-centre trial RCT IDO Awaited Allergan phase III multi-centre trial RCT IDO 2004 IC Smith et al 2009 RCT Kuo et al BO / Sensory urgency 2010 Allergan Phase II multi-centre trial RCT 2011 RCT BO Dowson et al 1
10 RCT IDO 200 U Results 16 BTX; 18 Placebo Flexible cystoscopy technique Results: QoL Mean Value IIQ-7 UDI-6 BTX-A Placebo Difference between means (95% Cl) Baseline NS 4 weeks 6.00 ( 12.31) ( 4.11) ( to -0.78) weeks 7.94 ( 10.38) (+0.61) ( to -2.50) Baseline NS 4 weeks 5.60 ( 5.15) 9.00 ( 0.50) (-6.17 to -2.08) weeks 5.13 ( 5.63) (+0.50) (-7.83 to -2.96) < P KHQ Domain scores Domain 4/52 12/52 24/52 General Health Perception Incontinence Impact* <0.0001* * * Symptom Severity Score* * * * Role Limitations * * Physical Limitations* * * * Social Limitations* * * * Personal Relationships * Emotions* * * * Sleep / Energy * * Severity Measures* * * * Extension study / safety 6 month extension study Average pain scores: 4.25 BTX; 4.0 Placebo (Non significant) Adverse events: CISC 6/16 (37.5%) in those who received BTX UTI 7/34 (20.5%) but 6 performing CISC 2
11 RCT IDO 2 Females with refractory IDO 200 U OAB Sx + UUI 60% clinical response Efficacy 1 year Adverse Events CISC 43% UTI N=22 Allergan 077 Phase II study 3
12 N=313 Randomised placebo controlled trial Dose escalation ( IU) IDO and BO allowed Treatment consisted of 20 injections (0.5 ml per site) Results Weekly UUI KHQ Urodynamics Conclusions 100 IU best balance between efficacy and AE Phase III data awaited 4
13 Guy s Experience Not one dose will fit all Guy s Experience Tailored approach per patient Dose escalation for efficacy? Reduction for AEs Guy s Experience Repeat Injections Results Results PBS / IC Few studies Small numbers Kuo et al., BJUI 2009 BTX + HD N=67 70% success 5
14 Questions?? 6
15 Botulinum Toxin injections for Overactive Bladder: Mechanism of Action Prokar Dasgupta ICS 2012 Summary Efferent effect NMJ Afferent effect Non-neuronal neurotransmitters Neurotrophins Inflammatory effect Schiavo G et al. (1990) J Physiol (Paris) 84:
16 Instillation vs Injection Cleaved SNAP 25 Coelho et al, European Urology, June 2012 Coelho et al, European Urology, June 2012 Apostolidis et al, European Urology 49(2006) Kanai et al, Neuro-urology and Urodynamics, 2011 Kanai et al. Neurourology and Urodynamics 30: (2011) Recording single unit afferent nerve firing Animal bladders Demonstrate a correlation between spontaneous contractions and afferent nerve firing in SCT mice BTX-A seen to subsequently reduce afferent nerve recordings and hence firings 2
17 Pre No change in suburothelial neuronal population post BoNT/A Suburothelial nerve fibres (PGP9.5) and BoNT/A Post % red area PGP9.5 Apostolidis A, et al. J Urol Pre Apostolidis 4/52 A, et al. Post J Urol 2005 Pre 4/52 Post NDO IDO Increased afferent suburothelial innervation in DO Apostolidis A, et al. J Urol 2005 Suburothelial P2X 3 after BoNT/A Progressive decrease and normalisation Apostolidis A, et al. J Urol 2005; 174: P2X 3 * 0.75 TRPV1 * 1.5 P2X 3 Nerve density Controls NDO IDO Nerve density Controls NDO IDO Nerve density * ** 0.0 Controls Pre 4/52 16/52 Suburothelial TRPV1 after BoNT/A Apostolidis A, et al. J Urol 2005; 174: UroNeurology, NINN TRPV Nerve fibre density * Successful treatment of OAB with BTX-A is associated with a significant decrease of TRPV1and/or P2X3 levels toward control values. BoNT/A may act directly on the afferent innervation of the bladder Controls Pre 4/52 16/52 BTX-A injections do not appear to produce significant inflammatory changes, fibrosis, or dysplastic changes in human bladder urothelium/suburothelium after a single injection and in a limited number of repeat treatment biopsies. Apostolidis et al., 2005; J Urol 3
18 Contractions per min Bladder contractions per minute 12/06/2012 NGF control urothelium Kuo et al., Rev Urol 2010 Citrate 1:100 Citrate - 1/200 Urine NGF levels decrease after successful treatment with BTX- A in IDO and NDO No decrease in levels in nonresponders to BTX-A Citrate 1:400 Tissue NGF levels pre and post BTX-A in Interstitial Cystitis Wistar Rats Intravesical Saline Intravesical BoTN/A Acetic acid NGF Saline Acetic acid NGF Saline Liu et al, Urology 2007 C-fibre stimulation A-delta fibre stimulation Outcome measure: frequency of bladder contractions Frequency of bladder contraction at fixed rate for 2hours Saline 0.08ml/min 0.3% Acetic acid 0.3% Acetic acid + botn-a Infusion substance Botn-A infusion significantly attenuates the response of the bladder to an acetic acid infusion (p=0.04) Frequency of bladder contraction at increasing rates of bladder fill % acetic acid Infusion rate Botn-A infusion has no significant effect on the response of the bladder to an increasing filling rate of normal saline. Botn-A Sham 4
19 NGF Effect NGF and BDNF Pinto et al, European Urology 2010 Trigonal injections of BTX-A for PBS Botn-A significantly attenuates the response of the bladder to a 30 min infusion of NGF compared to placebo BTX-A and inflammatory markers COX2 and EP4 Chuang et al, European Urology 2009 Safety - inflammation Apostolidis et al, European Urology 2008 Further research areas. Mechanisms of action IC / painful bladder / Sensory urgency Interstitial cells Conclusions Efferent effect NMJ Afferent effect Non-neuronal neurotransmitters Neurotrophins Biomarkers Hence effective for IDO/NDO Role in inflammatory conditions e.g interstitial cystitis 5
20 IDO What I Do Dr Muhammad Shamim Khan Consultant Urologist Hx / Ex Assess for confounding issues: -previous surgery -mixed incontinence -prolpase Refractory OAB ie failed anti-cholinergics and conservative measures URODYNAMICS!! Dose U- Not for everyone NDO Patient Information 1 Tend to be better worked up Have had good assessment usually Typical scenario UUI despite CISC / anticholinergics Dose 200 U Unlicensed for IDO and for NDO in UK Significant OAB ; failed anti-cholinergics Not life long ; One injection per year Patient information 2 Incomplete bladder emptying UTIs Flu Haematuria Distal muscle weakness CISC can they do it? To be avoided if Bladder outflow obstruction Anticoagulants Bladder pathology eg fibrosis, tcc, DXT etc Pregnancy / planning pregnancy 1
21 Equipment Injection technique Key Points-Technique Techniques-variations Rigid cystoscope using a collagen-flexible needle LA; prophylactic antibiotics ; Day Case Don t shake vial! 10 U/mL/site Mapping of posterior, lateral walls and dome -trigone sparing!! Harper et al., 2003; Sahai et al., 2006; Schulte-Baukhloh et al., 2005 Flexi cystoscope using ultra fine 4mm flexible needle Trigonal vs trigone sparing techniques Detrusor vs suburothelium Number of injections; Volume of injection Mode of delivery Variations in technique and research Indigo carmine injection Schulte-Baukloh et al., BJUI 2005; Focussed bladder base and trigonal injections (left NDO; right IDO / IC) Smith & Chancellor J Endourol 2005; Does technique matter?? Majority of experts- No; Others Yes Manecksha et al Eur Urol 2012 RCT Trigone sparing vs Trigone + Bladder Combined showed better subjective efficacy but no change in UDS Small numbers/ Performed under GA; Feasibility of trigonal LA injection MRI study post injection with contrast; 18% outside detrusor rigid scope technique Mehnert et al., World J Urol
22 Evidence-Summary Trigone inclusive injections appear to be more efficacious with slightly increased risk of CISC Trigone alone - inferior in efficacy but less risk of CISC 100 U Detrusor > suburothelial > bladder base OAB symtoms similar in all MCC increased in detrusor and suburothelial Bladder base no retention and lowest PVRs; but less duration of action. Satisfaction at 3/12 80%, 93% and 67% BTA-instillation does not work & effect if any very short lived Animal experiments with combination of liposomes and botox (lipotoxin) have shown some promise!! 3
23 Notes Record your notes from the workshop here
Botulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationUse of botulinum toxin for voiding dysfunction
Review Article Use of botulinum toxin for voiding dysfunction David Eldred-Evans, Prokar Dasgupta Department of Urology, Medical Research Council (MRC) Centre for Transplantation, King s College London,
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationOnabotulinumtoxinA for the treatment of overactive bladder
OnabotulinumtoxinA for the treatment of overactive bladder Clin. Invest. (2014) 4(3), 281 286 OnabotulinumtoxinA has recently been granted a license for use in overactive bladder (OAB). This review assesses
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationProspective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
Original Article Prospective randomized trial of vs botox in the treatment of idiopathic overactive bladder Waleed AlTaweel, Alaa Mokhtar, Danny M. Rabah 1 King Faisal Specialist Hospital and Research
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationHasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran
ORIGINAL ARTICLE Vol. 43 (6): 1122-1128, November - December, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0622 Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity:
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum
More informationREVIEW ARTICLE. Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder
76 REVIEW ARTICLE Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder Marius Alexandru Moga, 1 Simona Banciu, 2 Oana Dimienescu, 3 Nicusor-Florin Bigiu, 4 Ioan Scarneciu 5 Abstract
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationUse of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity
Use of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity Editorial Raluca Borcăiaș 1,2, A. Manu-Marin 3, S. Nedelea 1,2, S. Rascu 1,2, V. Jinga 1,2 1 Prof. Dr. Th. Burghele
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More informationBOTULINUM TOXIN POLICY TO INCLUDE:
BOTULINUM TOXIN POLICY TO INCLUDE: Blepharospasm in adults, Hemi facial spasm in adults, spasmodic torticollis (cervical dystonia), focal spasticity treatment of dynamic equinus foot deformity, focal spasticity
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other ONABOTULINUMTOXINA BOTOX 04867 BRAND BOTOX COSMETIC ABOBOTULINUMTOXINA DYSPORT 36477 RIMABOTULINUMTOXINB MYOBLOC 21869 INCOBOTULINUMTOXINA XEOMIN 36687 Please use
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 784 795 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Neuro-urology Contemporary Management of Lower Urinary Tract Disease
More informationIntravesical Drug Delivery for Dysfunctional Bladder
Intravesical Drug Delivery for Dysfunctional Bladder Yao-Chi Chuang Professor and Chief, Division of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan 成長於台南 建興國中 台南一中 2 Yao-Chi Chuang In connection
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 891 896 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory
More informationBOTOX (onabotulinumtoxina) for Therapeutic Use
BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) & BOTOX Cosmetic (onabotulinumtoxina) Important Information IMPORTANT SAFETY INFORMATION BOTOX and BOTOX Cosmetic may cause serious
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationScientific Update Laxman Bahroo, MD
Scientific Update Laxman Bahroo, MD Associate Professor Director; Botulinum Toxin Clinic Director; Neurology Residency Program Medstar Georgetown University Hospital Washington, D.C. Disclosures Advisory
More informationNeural control of the lower urinary tract in health and disease
Neural control of the lower urinary tract in health and disease Jalesh N. Panicker MD, DM, FRCP Consultant Neurologist and Clinical lead in Uro-Neurology The National Hospital for Neurology and Neurosurgery
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationO (P =.005) in the NDO group and from ± 9.92 cmh 2. O to ± cmh 2
MISCELLANEOUS Success Rate and Patients' Satisfaction Following Intradetrusor Dysport Injection in Patients with Detrusor Overactivity: A Comparative Study of Idiopathic and Neurogenic Types of Detrusor
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationVoiding Dysfunction. Yao-Chi Chuang,* Jonathan H. Kaufmann, David D. Chancellor, Michael B. Chancellor and Hann-Chorng Kuo,k
Voiding Dysfunction Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial Yao-Chi Chuang,* Jonathan
More informationMEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection
17.2 Ability to Operate Machinery or Vehicles Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationBOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationNeural control of the lower urinary tract
Neural control of the lower urinary tract Jalesh N. Panicker Consultant Neurologist and Honorary Senior Lecturer The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen
More informationA Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationA joint venture between the Department of Uro-Neurology, Queen Square, University College London and the Neuro-Urology Promotion Committee of the ICS
Neurogenic bladder 2-day course A joint venture between the Uro-Neurology,, University College London and the Neuro-Urology Promotion Committee of the ICS November 27 and 28, 2014 Venue: Clinical Neuroscience
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More informationUrinary Incontinence. Lora Keeling and Byron Neale
Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,
More informationeuropean urology 53 (2008)
european urology 53 (2008) 1245 1253 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Histological Changes in the Urothelium and Suburothelium of Human Overactive
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2016) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler. Guidelines Associates:
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2013) 30:819 833 DOI 10.1007/s25-013-0054-z ORIGINAL RESEARCH OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant
More informationEMR template and postprocedure notes
EMR template and postprocedure notes Sample autopopulated text to create a BOTOX injection procedure report Information gathered from market research. These considerations are for reference only and should
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 10 Last Review Date: November 30, 2018 Botox Description Botox (onabotulinum
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationBotulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )
Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) These services may or may not be covered by your HealthPartners
More informationBotox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)
Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date:
More informationA thesis submitted in partial fulfillment of the requirements for the degree in Master of Science
Western University Scholarship@Western Electronic Thesis and Dissertation Repository September 2012 A Pilot Trial Comparing the Effects of Onabotulinumtoxina and Standard Oxybutynin Therapy as First Line
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationNeurological control of the bladder in health and disease
Section 1 Chapter 1 Neurological control of pelvic organ functions Neurological control of the bladder in health and disease Derek J. Griffiths and Apostolos Apostolidis Peripheral control of micturition
More informationIntroduction. Spinal Cord Injury (SCI) Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients?
Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients? Rizwan Hamid MBBS, FRCSEd, FRCS(Urol), MD(Res) Honorary Senior Lecturer & Consultant Urologist
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationNeuroanatomy, Neurophysiology and Clinical Presentation of Visceral Urological Pain
Neuroanatomy, Neurophysiology and Clinical Presentation of Visceral Urological Pain Prof Dr K. Everaert Functional urology Department of Urology Ghent University Hospital Gent, Belgium Chronic pelvic pain
More informationApril Clinical Focus Topic URINARY FREQUENCY
April Clinical Focus Topic URINARY FREQUENCY This month I am focusing on a topic that may seem a little boring. But I would like to look at it from a less common perspective.urinary Frequency and its relationship
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationBotulinum Toxin Injection: A Review of Injection Principles and Protocols
Review Article Botulinum Toxin Injection International Braz J Urol Vol. 33 (2): 132-141, March - April, 2007 Botulinum Toxin Injection: A Review of Injection Principles and Protocols David E. Rapp, Alvaro
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationExperience with Different Botulinum Toxins for the Treatment of Refractory Neurogenic Detrusor Overactivity
Neurourology Botulinum Toxins for Refractory Detrusor Overactivity International Braz J Urol Vol. 36 (1): 66-74, January - February, 2010 doi: 10.1590/S1677-55382010000100011 Experience with Different
More informationeuropean urology 55 (2009)
european urology 55 (2009) 100 120 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Recommendations on the Use of Botulinum Toxin in the Treatment of Lower
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2017) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler Guidelines Associates:
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationAbbreviated Class Review: Botulinum toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationUrinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives Arun Sahai PhD, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Lecturer Guy s Hospital
More informationPractical urodynamics What PA s need to know. Gary E. Lemack, MD Professor of Urology and Neurology
Practical urodynamics What PA s need to know Gary E. Lemack, MD Professor of Urology and Neurology Urodynamics essential elements Urethral catheter Fill rate Catheter size Intravesical pressure measurements
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationeuropean urology 53 (2008)
european urology 53 (2008) 275 287 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Botulinum Toxin A (Botox W ) Intradetrusor Injections in Adults with
More informationNeuromuscular Blocking Agents
Neuromuscular Blocking Agents DRUG POLICY This Prior Authorization request will be reviewed for medical necessity only. Benefits are subject to the terms and conditions of the patient s contract. Please
More informationBotulinum Toxin a promising new treatment for overactive bladder
Botulinum Toxin a promising new treatment for overactive bladder C. Persu 1, D. Castro-Diaz 2, S.C. Gutui 3, J. Lavelle 3, P. Geavlete 1 1 Spitalul Clinic Sf Ioan, Bucuresti 2 University Hospital of Canary
More informationƒ( t, l, c ) The Use of Botox Injection in the Treatment of the Neurogenic Bladder Bladder ( Sphincter ) Dysfunction Dr C K Chan 95%
The Use of Botox Injection in the Treatment of the Neurogenic Bladder Dr C K Chan Division of Urology Department of Surgery Prince of Wales Hospital EAU guidelines 2003 / 2006 Neurologic disease Dementia
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationSpinal Cord Injury. R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH
Spinal Cord Injury R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH SCI 800 1000 new cases per year in UK Car accidents 35%
More informationIs OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20
1 2 3 4 5 6 Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20 years Efficacy of BoNT type A (onabotulinumtoxina,
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationAnnual Scientific Update in Urogynaecology- Joint RCOG/BSUG Meeting Neurogenic bladder dysfunction
Annual Scientific Update in Urogynaecology- Joint RCOG/BSUG Meeting Neurogenic bladder dysfunction Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Aims Background
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Assessment and investigation of urinary incontinence in women bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationUrodynamics Mismatch - Should We Listen to the Study, or the Patient?
Urodynamics Mismatch - Should We Listen to the Study, or the Patient? A Practical Approach to the Diagnosis and Treatment of Lower Urinary Tract Dysfunction Victor W. Nitti MD Professor of Urology and
More information